

# IMUGENE

## Animal Health Biological Products


### 2006 Annual Review – Highlights & Update

November 2006

*Dr Warwick Lamb*

*Managing Director*

**IMUGENE**  
  
**LIMITED**



# IMUGENE

## Product & Industry Focus

- **Biological animal health products**
- **Proven & patented platform science**
- **Advanced products with market demand & need**
- **Strong product pipeline**
- **Early licensing success**
- **Early regulatory approvals**



# Highlights

## Poultry Productivity Enhancer

- **Licensed to Merial in Oct 2005**
- **Completion of two Australian safety trials**
- **Sign-up fees received & milestone payment recently earned**
- **Progressing through product development for global and Australian commercial releases**

# Highlights

## Avian Influenza

- **Two vaccine candidates completed**
  - For broilers & layers/breeders
- **Fully lab tested**
- **High quality trial site secured in US**
- **Poultry trials to commence this quarter**
- **Successful grant funding of \$882,000 for product development**
- **International interest**

# Highlights Coccidiosis

- **Vaccine candidates completed**
- **Final candidate verification underway**
- **Expect to handover to Teva/Abic for poultry trials in early 2007**
- **Anticipate licensing FAV for delivery of these vaccines if successful in trials**

# Highlights Patents

- **Successfully defended US interference proceedings for PAV**
- **Improved patent position in US with patent assignment**
- **Lodged new patent for PAV in US**
  - **Prolonged commercial protection**
- **FAV patent granted in Europe**

# Highlights

## Imugene Laboratory

- **Successfully established our own leasehold laboratory facility at La Trobe University**
- **Significant improvement in scientific progress – both quality and timeframes**
- **Focused commercial research**
- **Marked improvement in product quality control**



# Highlights Regulatory

- **New Imugene Institutional Biosafety Committee**
- **Applications lodged for OGTR licences for PAV and FAV laboratory work**
- **Intentional Release application for the Poultry Productivity Enhancer for final submission to OGTR**

# Update Pig Vaccines

- **PAV-PRRS US trial site**
  - Final negotiation phase
- **PAV-Merial product improvements**
- **PAV pipeline – product dependent pathways**

# Activity

## 1<sup>ST</sup> Half 2007

- **Expanding Imugene's animal health reputation in US and Europe**
- **Further US based product trials**
- **Advancing international commercial arrangements**

# Activity – Poultry

## 1<sup>ST</sup> Half 2007

- **Avian flu trial**
  - To be completed Jan 2007
  - Interim results – Jan 2007
  - Full results – first quarter 2007
- **Poultry Productivity Enhancer**
  - Regulatory progress – OGTR
  - Product development funded by Merial
- **Coccidiosis**
  - Vaccine constructs to be trialled by Teva / Abic

# Activity – Pigs

## 1<sup>ST</sup> Half 2007

- **Pig vaccines**
  - US based PRRS vaccine trial
  - Improved PAV-Merial vaccines constructed and delivered to Merial
  - Other PAV products developed for disease specific markets
- **PAV patents**
  - International prosecution of new PAV patent

# Update Financial Position

- **Net cash outflow – \$137k/mth = under budget**
- **2007 budget approx \$150k/mth**
- **Merial funding development work on Poultry Productivity Enhancer**
- **\$2.3m cash – Sep 06**
- **\$880k Government grant for Bird Flu – 2 years**
- **Financial returns from Merial licence**
- **Contract payments due from Teva/Abic**
- **Teva/Abic to fund trials & product development**

# Update Corporate

## Directors & management

- Graham Dowland – Chairman
- Warwick Lamb – CEO
- Roger Steinepreis – Director
- Mike Sheppard – Chief Scientific Officer

- **Shares on issue** **130 m**  
(QIC – 5.7%, Board – 13%)
- **Options on issue**
  - Expiry 31 Dec 06 (25c-30c) **6.2 m**
  - Expiry 31 Jan 07 (50c) **4.5 m**
  - Expiry 31 Oct 07 (22.5c-37.5c) **4.9 m**